C. Isaacs

发表

Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.

J. Gohagan, P. Prorok, B. Kramer, 2011, JAMA.

Author Correction: Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis

C. Isaacs, V. Jin, Xiaowen Zhang, 2018, Nature communications.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Michael Hogarth, Lajos Pusztai, Rita Nanda, 2016, The New England journal of medicine.

Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations

J. Garber, C. Isaacs, I. Bedrosian, 2019, The breast journal.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

J. Gohagan, P. Prorok, B. Kramer, 2012, Journal of the National Cancer Institute.

All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results.

C. Isaacs, B. Peshkin, M. Schwartz, 2002, American journal of medical genetics.

Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations.

W. Lawrence, C. Isaacs, B. Peshkin, 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

F. Couch, B. Karlan, J. Klijn, 2007, Breast Cancer Research and Treatment.

Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

O. Olopade, B. Karlan, W. Foulkes, 2005, Cancer Causes & Control.

Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study.

C. Gatsonis, D. Bowen, C. Lehman, 2007, Radiology.

Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States.

W. Willett, T. VanderWeele, S. Chanock, 2016, JAMA oncology.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jaana M. Hartikainen, W. Chung, 2019, Nature Genetics.

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

J. Gohagan, P. Prorok, B. Kramer, 2011, JAMA.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Lara E Sucheston-Campbell, Simon G. Coetzee, Lara E. Sucheston-Campbell, 2017, Nature Genetics.

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

Susan L Neuhausen, Olufunmilayo I Olopade, Judy E Garber, 2002, The New England journal of medicine.

Utilizing prognostic and predictive factors in breast cancer

C. Isaacs, Claudine Isaacs, Deepa S. Subramaniam, 2005, Current treatment options in oncology.

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.

E. Winer, R. Schilsky, C. Hudis, 2011, European journal of cancer.

Germline genetic variants in ABCB1, ABCC1, and ALDH1A1 and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer

G. Hortobagyi, Song Liu, C. Isaacs, 2013, The Pharmacogenomics Journal.

Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.

Mads Thomassen, Etienne Rouleau, Dieter Niederacher, 2010, Cancer research.

ROLE OF ESTROGEN IN FAMILIAL BREAST CANCER

C. Isaacs, E. Rosen, 2013 .

Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.

C. Magnant, C. Isaacs, B. Peshkin, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers

Daniel L Gillen, Susan L Neuhausen, Fergus Couch, 2009, Breast Cancer Research.

Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers

F. Couch, O. Olopade, T. Rebbeck, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.

F. Couch, T. Rebbeck, R. Eeles, 2007, Clinical breast cancer.

Psychological and Behavioral Impact of BRCA1/2 Genetic Testing

T. Rebbeck, C. Isaacs, M. Schwartz, 2007 .

Development of an Interactive Decision Aid for Female BRCA1/BRCA2 Carriers

H. Valdimarsdottir, C. Isaacs, B. Peshkin, 2003, Journal of Genetic Counseling.

Results From Four Rounds of Ovarian Cancer Screening in a Randomized Trial

Timothy R Church, Christine C Johnson, Edward Partridge, 2009, Obstetrics and gynecology.

Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer

R. Gray, C. Isaacs, J. Mandelblatt, 2019, JNCI cancer spectrum.

Hormone replacement therapy in women with a history of breast carcinoma.

C. Isaacs, S. Swain, 1994, Hematology/oncology clinics of North America.

Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.

C. Isaacs, B. Peshkin, M. Schwartz, 2003, Journal of Clinical Oncology.

Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.

O. Olopade, B. Weber, C. Berg, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes

Jack A. Taylor, W. Chung, S. Cross, 2019, bioRxiv.

Exploring Racial Differences in Treatment Decision-making in Chinese Immigrant and White American Breast Cancer Patients: the Role of Patient-Provider Communication

C. Isaacs, V. Sheppard, J. Wang, 2021, Journal of Cancer Education.

Circulating Insulin-like Growth Factor (IGF)-I and IGF Binding Protein (IGFBP)-3 Levels and Postmenopausal Breast Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort

C. McCarty, R. Ziegler, C. Berg, 2010, Hormones & cancer.

Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers

J. Klijn, P. Møller, G. Rennert, 2008, Journal of the National Cancer Institute.

Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

B. Karlan, P. Møller, C. Isaacs, 2006, Gynecologic oncology.

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

F. Couch, O. Olopade, J. Klijn, 2002, Journal of the National Cancer Institute.

Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study

C. Isaacs, S. Neuhausen, N. Tung, 2001, The Lancet.

Hereditary Breast Cancer: an Overview

C. Isaacs, B. Peshkin, 1999 .

Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

O. Olopade, T. Rebbeck, R. Eeles, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Pilot Study to Establish a Clinical Model to Perform Phase II Studies of Breast Cancer Chemopreventive Agents in Women at High Risk with Biomarkers as Surrogate Endpoints for Activity

B. Trock, Baljit Singh, C. Isaacs, 2004, Clinical Cancer Research.

Perceived risk of breast cancer among Latinas attending community clinics: risk comprehension and relationship with mammography adherence

C. Isaacs, J. Mandelblatt, V. Sheppard, 2008, Cancer Causes & Control.

Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.

C. Isaacs, F. Lynce, 2016, The Journal of the National Comprehensive Cancer Network.

Population-Based BRCA 1 / 2 Testing in Ashkenazi Jews : Ready for Prime Time

C. Isaacs, F. Lynce, 2016 .

PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer

C. Isaacs, P. Pohlmann, A. Shajahan-Haq, 2018, Contemporary clinical trials communications.

Applying a Life Course Biological Age Framework to Improving the Care of Individuals With Adult Cancers: Review and Research Recommendations.

A. Saykin, C. Isaacs, J. Mandelblatt, 2021, JAMA oncology.

Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk

A. Whittemore, W. Chung, L. Kiemeney, 2020, medRxiv.

A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11.

Jane E. Carpenter, Daniel J. Park, Gary K. Chen, 2012, Human molecular genetics.

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

M. Somerfield, C. Isaacs, M. Robson, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conveying genomic recurrence risk estimates to patients with early‐stage breast cancer: oncologist perspectives

C. Isaacs, B. Peshkin, M. Schwartz, 2013, Psycho-oncology.

Deleterious BRCA1/2 mutations in an urban population of Black women

C. Isaacs, B. Peshkin, Hongkun Wang, 2015, Breast Cancer Research and Treatment.

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2

B. Bonanni, T. Rebbeck, J. Benítez, 2011, British Journal of Cancer.

Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

W. Foulkes, B. Weber, C. Isaacs, 2005, Breast Cancer Research.

Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

D. Horsman, W. Foulkes, B. Weber, 2004, Journal of the National Cancer Institute.

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers

Mads Thomassen, Nina Ditsch, Vijai Joseph, 2012, Breast Cancer Research.

Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival.

G. Hortobagyi, A. Hutson, C. Isaacs, 2020, Journal of the National Cancer Institute.

Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination.

P. Prorok, J. Rathmell, E. Crawford, 2012, Journal of the National Cancer Institute.

Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing.

C. Magnant, C. Isaacs, B. Peshkin, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Susan L Neuhausen, Olufunmilayo I Olopade, Judy E Garber, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients

H. Valdimarsdottir, C. Isaacs, Elizabeth Poggi, 2020, Breast Cancer Research and Treatment.

Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few.

C. Isaacs, P. Pohlmann, 2018, Journal of the National Cancer Institute.

Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy

C. Isaacs, N. Brewer, M. Schwartz, 2016, Breast Cancer Research and Treatment.

Treatment of primary breast tumors in de novo metastatic breast cancer.

C. Isaacs, Theresa M. Lee, 2014, Clinical advances in hematology & oncology : H&O.

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

F. Couch, O. Olopade, J. Klijn, 2002, Journal of the National Cancer Institute.

Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)

M. Thun, F. Clavel-Chapelon, E. Riboli, 2009, BMC Cancer.

Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers

Jinbo Chen, F. Couch, O. Olopade, 2014, Breast Cancer Research and Treatment.

Abstract PD8-04: Racial differences in the molecular landscape of breast cancer

C. Isaacs, S. Swain, Z. Gatalica, 2017 .

Long-term risk of medical conditions associated with breast cancer treatment

L. Strong, J. Berg, C. Isaacs, 2014, Breast Cancer Research and Treatment.

Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium.

Peter Kraft, Salvatore Panico, Mattias Johansson, 2011, Journal of the National Cancer Institute.

Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States.

W. Willett, T. VanderWeele, S. Chanock, 2016, JAMA oncology.

Association of markers of tumor aggressivity and cognition in women with breast cancer before adjuvant treatment: The Thinking and Living with Cancer Study

A. Saykin, B. McDonald, C. Isaacs, 2022, Breast Cancer Research and Treatment.

Estrogen metabolism and risk of breast cancer in postmenopausal women.

R. Hoover, M. Gail, T. Veenstra, 2012, Journal of the National Cancer Institute.

Long-Term Psychosocial Outcomes of BRCA1/BRCA2 Testing: Differences across Affected Status and Risk-Reducing Surgery Choice

C. Isaacs, Elizabeth Poggi, B. Peshkin, 2012, Cancer Epidemiology, Biomarkers and Prevention.

Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives

C. Isaacs, J. Clapp, J. Mandelblatt, 2018, Journal of health communication.

Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients

H. Valdimarsdottir, C. Isaacs, B. Peshkin, 2018, Breast Cancer Research and Treatment.

Detection of LOH and Mitochondrial DNA Alterations in Ductal Lavage and Nipple Aspirate Fluids from High-risk Patients

Minetta C. Liu, Baljit Singh, C. Isaacs, 2004, Breast Cancer Research and Treatment.

Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.

C. Isaacs, J. Lubiński, N. Tung, 2009, Gynecologic Oncology.

Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

David A Lynch, John K Gohagan, Carl R Fuhrman, 2010, Journal of the National Cancer Institute.

Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.

L. Esserman, D. Yee, C. Yau, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors

C. Isaacs, B. Peshkin, M. Schwartz, 2006, Breast Cancer Research and Treatment.

Breast and Ovarian Cancer Screening Practices in Healthy Women with a Strong Family History of Breast or Ovarian Cancer

C. Isaacs, B. Peshkin, M. Schwartz, 2004, Breast Cancer Research and Treatment.

Alcohol and risk of breast cancer in postmenopausal women: an analysis of etiological heterogeneity by multiple tumor characteristics.

N. Chatterjee, R. Ziegler, S. Buys, 2014, American journal of epidemiology.

Hormone Therapy and the Risk of Breast Cancer in BRCA 1 Mutation Carriers

J. Klijn, P. Møller, G. Rennert, 2008 .

Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.

P. Møller, W. Foulkes, C. Isaacs, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.

C. Isaacs, B. Peshkin, M. Schwartz, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing.

C. Isaacs, B. Peshkin, M. Schwartz, 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Cancer variation associated with the position of the mutation in the BRCA2 gene

D. Horsman, B. Weber, J. Garber, 2004, Familial Cancer.

Systemic Therapy for BRCA-Associated Breast Cancer

T. Rebbeck, C. Isaacs, M. Robson, 2007 .

Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update

J. Klijn, P. Møller, W. Foulkes, 2009, Breast Cancer Research and Treatment.

Predictors of Enrollment into a Familial Cancer Registry by Individuals at High Risk for BRCA1/2

C. Isaacs, B. Peshkin, M. Schwartz, 2006, Cancer Epidemiology Biomarkers & Prevention.

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

Annette Lee, W. Chung, R. Nussbaum, 2018, Human mutation.

How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing.

C. Isaacs, F. Lynce, Claudine Isaacs, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk.

C. Isaacs, J. Benkendorf, A. Gomez‐Caminero, 1997, Patient education and counseling.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.

Rosalyn W. Sayaman, E. Petricoin, L. Esserman, 2022, Cancer cell.

Additive interactions between susceptibility single-nucleotide polymorphisms identified in genome-wide association studies and breast cancer risk factors in the Breast and Prostate Cancer Cohort Consortium.

Peter Kraft, Vittorio Krogh, Tyler J VanderWeele, 2014, American journal of epidemiology.

Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin.

N. Robert, C. Isaacs, B. Overmoyer, 1997, Journal of Clinical Oncology.

Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers

R. Nussbaum, F. Couch, J. Benítez, 2017, European Journal of Human Genetics.

Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

W. Chung, R. Nussbaum, F. Couch, 2016, Breast Cancer Research and Treatment.

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers

V. Pankratz, F. Couch, B. Bonanni, 2012, Breast Cancer Research.

Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis

T. Rebbeck, S. Gruber, E. Iversen, 2010, Breast Cancer Research and Treatment.

Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

W. Chung, F. Couch, B. Bonanni, 2020, JAMA oncology.

BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry

Annette Lee, F. Couch, O. Olopade, 2019, Human mutation.

Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers

F. Couch, O. Olopade, T. Rebbeck, 2010, Breast Cancer Research and Treatment.

Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway

C. Isaacs, S. Swain, A. Tan, 2020, Breast Cancer Research and Treatment.

Age-associated risks of prophylactic anticoagulation in the setting of hip fracture

M. Beaudet, C. Isaacs, O. Paltiel, 1994 .

Family Disclosure in Genetic Testing for Cancer Susceptibility: Determinants and Consequences

C. Isaacs, B. Peshkin, C. Lerman, 1998 .

Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers

F. Couch, O. Olopade, J. Klijn, 2005, International journal of cancer.

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.

J. Gregg, C. Savran, C. Isaacs, 2020, JAMA oncology.

Association of markers of tumor aggressivity and cognition in women with breast cancer before adjuvant treatment: The Thinking and Living with Cancer Study

A. Saykin, B. McDonald, C. Isaacs, 2022, Breast Cancer Research and Treatment.

Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).

C. Isaacs, Bing-he Xu, F. André, 2013 .

Hot flushes

C. Isaacs, D. Hayes, J. F. Lopez, 2002, The Lancet.

RE: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

C. Isaacs, B. Peshkin, M. Schwartz, 2019, Journal of the National Cancer Institute.

Uptake of BRCA1/2 Genetic Testing in a Randomized Trial of Telephone Counseling

J. Garber, H. Valdimarsdottir, C. Isaacs, 2014, Genetics in Medicine.

Cancer yield of mammography, MRI, and ultrasound in high-risk women enrolled in a prospective multi-institution breast cancer screening trial.

C. Lehman, E. Pisano, D. Bluemke, 2004, Journal of Clinical Oncology.

Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk.

C. Isaacs, J. Garber, B. Peshkin, 2022, Pediatrics.

Identiﬁcation of four novel susceptibility loci for oestrogen receptor negative breast cancer

Nussbaum, S. Cross, P. Fasching, 2016 .

Ophira M. GinsburgCharmaine Kim-SingWilliam D. Foulkes • Parviz GhadirianHenry T. LynchPing SunSteven A. Narod • Hereditary Breast Cancer Clinical Study Group

F. Couch, O. Olopade, B. Karlan, 2010 .

Smoking and the risk of breast cancer among carriers of BRCA mutations

D. Horsman, W. Foulkes, B. Weber, 2004, International journal of cancer.

Psychosocial impact of proactive rapid genetic counseling following breast cancer diagnosis

H. Valdimarsdottir, C. Isaacs, B. Peshkin, 2021, Psycho-oncology.

Question Prompt List to Support Patient-Provider Communication in the Use of the 21-Gene Recurrence Test: Feasibility, Acceptability, and Outcomes.

R. Street, C. Isaacs, S. Vadaparampil, 2020, JCO oncology practice.

Validity of Models for Predicting BRCA1 and BRCA2 Mutations

Leif E. Peterson, Giovanni Parmigiani, Li Hsu, 2007, Annals of Internal Medicine.

Age-associated risks of prophylactic anticoagulation in the setting of hip fracture.

M. Beaudet, C. Isaacs, O. Paltiel, 1995, The American journal of medicine.

Supplement use during an intergroup clinical trial for breast cancer (S0221)

G. Hortobagyi, C. Isaacs, J. Unger, 2013, Breast Cancer Research and Treatment.

Molecular characterization of ESR1 variants in breast cancer

M. Oberley, C. Isaacs, S. Swain, 2022, Breast Cancer Research and Treatment.

S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.

G. Hortobagyi, C. Isaacs, R. Livingston, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Male breast cancer in BRCA1 and BRCA2 mutation carriers

R. Nussbaum, D. Steinemann, F. Couch, 2018 .

Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.

C. Isaacs, F. André, M. Riester, 2015 .

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

W. Chung, D. Steinemann, F. Couch, 2022, Communications Biology.

Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221).

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, G. Hortobagyi, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, G. Hortobagyi, 2017, Journal of the National Cancer Institute.

Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer

C. Isaacs, M. Tan, P. Pohlmann, 2021, Cancer.

Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

B. Karlan, P. Møller, C. Isaacs, 2006, Gynecologic oncology.

Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study

A. Saykin, B. McDonald, C. Isaacs, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers

Jan Lubinski, Charis Eng, Ping Sun, 2006, International journal of cancer.

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

Nicholas A. Sinnott-Armstrong, Richard C. Sallari, S. Cross, 2016, Nature Genetics.

Neratinib: an option for HER2-positive metastatic breast cancer.

C. Isaacs, J. O’Shaughnessy, R. O'Regan, 2020, Clinical advances in hematology & oncology : H&O.

Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers

O. Olopade, M. Southey, P. Miron, 2010, Journal of Medical Genetics.

JMEDGENET79814 1..5

O. Olopade, M. Southey, P. Miron, 2022 .

HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane

C. Isaacs, M. Tan, S. Swain, 2022, Breast Cancer Research and Treatment.

Prevalence of homologous recombination deficiency among all tumor types.

C. Isaacs, M. Pishvaian, F. Lynce, 2017 .

A planned, prospective comparison of short-term quality of life outcomes among older breast cancer patients treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901 ✰

Gretchen, C. Hudis, W. Barry, 2014 .

Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials

L. Rubinstein, C. Isaacs, P. Pohlmann, 2018, Breast Cancer Research and Treatment.

BRCA1/2 mutations and risk‐reducing bilateral salpingo‐oophorectomy among Latinas: The UPTAKE study

C. Isaacs, B. Peshkin, S. Friedman, 2020, Journal of Genetic Counseling.

Information and support needs of young women regarding breast cancer risk and genetic testing: adapting effective interventions for a novel population

C. Isaacs, B. Peshkin, S. Friedman, 2017, Familial Cancer.

Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980

E. Winer, R. Schilsky, C. Hudis, 2008 .

Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor–Positive Breast Cancer

C. Isaacs, J. Mandelblatt, C. Schechter, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Shared heritability and functional enrichment across six solid cancers

K. D. Sørensen, Stephanie A. Bien, Ali Amin Al Olama, 2019, Nature Communications.

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Adrian V. Lee, Gregory L. Wheeler, E. Mardis, 2022, Nature Cancer.

Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

C. Hudis, H. Rugo, C. Isaacs, 2013, Clinical Cancer Research.

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

Minetta C. Liu, C. Isaacs, G. Chung, 2010, Breast Cancer Research and Treatment.

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

C. Isaacs, Bing-he Xu, F. André, 2014, The Lancet. Oncology.

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.

D. Berry, L. Esserman, N. Hylton, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

C. Isaacs, F. André, M. Riester, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluating the impact of age on immune checkpoint therapy biomarkers

A. Weeraratna, E. Jaffee, C. Isaacs, 2021, Cell Reports.

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

Päivi Heikkilä, Mads Thomassen, Stephen Fox, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk.

E. Riboli, C. Guillemette, E. Weiderpass, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

D. Steinemann, F. Couch, B. Bonanni, 2020, Genetics in Medicine.

Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

Jack A. Taylor, W. Chung, S. Cross, 2019, bioRxiv.

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

Michael Jones, Peter Kraft, Arnaud Droit, 2017, Nature Genetics.

Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

W. Chung, R. Nussbaum, F. Couch, 2017, Journal of the National Cancer Institute.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

A. Whittemore, L. Kiemeney, S. Cross, 2016, Nature Communications.

Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

D. Steinemann, F. Couch, B. Bonanni, 2016, PloS one.

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

R. Nussbaum, D. Steinemann, F. Couch, 2016, Breast Cancer Research.

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

R. Nussbaum, D. Steinemann, V. Pankratz, 2014, Breast Cancer Research.

Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study

V. Pankratz, F. Couch, B. Bonanni, 2012, British Journal of Cancer.

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

J. S. Hoffman, W. Chung, V. Pankratz, 2012, Human mutation.

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2

Mads Thomassen, Stephen Fox, Dieter Niederacher, 2011, Breast Cancer Research.

A Comparison of Bilateral Breast Cancers in BRCA Carriers

O. Olopade, P. Møller, W. Foulkes, 2005, Cancer Epidemiology Biomarkers & Prevention.

Phase II evaluation of thalidomide in patients with metastatic breast cancer.

E. Winer, J. Hanfelt, L. Harris, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost Effectiveness of Gene Expression Profile Testing in Community Practice.

T. Lieu, C. Isaacs, S. Ramsey, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transcriptome ‐ wide association study of breast cancer risk by estrogen ‐ receptor status

Jack A. Taylor, W. Chung, S. Cross, 2020 .

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

Olufunmilayo I. Olopade, Mads Thomassen, Dieter Niederacher, 2016, Breast Cancer Research.

Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.

Baljit Singh, C. Isaacs, R. Dickson, 2004, Cancer Genetics and Cytogenetics.

Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.

P. Møller, W. Foulkes, C. Isaacs, 2006, The Lancet. Oncology.

Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

T. Rebbeck, J. Klijn, P. Møller, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).

E. Winer, S. Schnitt, J. Garber, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.

D. Berry, L. Esserman, N. Hylton, 2021, Cancer cell.

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.

D. Berry, L. Esserman, N. Hylton, 2020, JAMA oncology.

Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.

John L Marshall, C. Isaacs, J. Marshall, 2018, JCO precision oncology.

AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study

R. Vierkant, T. Sellers, V. Pankratz, 2007, Cancer Epidemiology Biomarkers & Prevention.

AURKA F 31 I Polymorphism and Breast Cancer Risk in BRCA 1 and BRCA 2 Mutation Carriers : A Consortium of Investigators of Modifiers of BRCA 1 / 2 Study

R. Vierkant, T. Sellers, J. Olson, 2007 .

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Genetics.

Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib

C. Isaacs, A. Wellstein, N. Shivapurkar, 2017, Clinical and Translational Medicine.

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

T. Rebbeck, R. Eeles, C. Hudis, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

M. Ellis, Y. Tao, L. Harris, 2007, Breast Cancer Research and Treatment.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Anne M Wallace, Michael Hogarth, Lajos Pusztai, 2016, The New England journal of medicine.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

Dong Liang, Patrick Neven, Harvey Risch, 2016, Journal of the National Cancer Institute.

A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk.

Harvey Risch, Yian A Chen, Mads Thomassen, 2018, Cancer research.

Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion

M. Pujana, C. Isaacs, V. Jin, 2021, Nature.

Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci

Lara E Sucheston-Campbell, G. T. Budd, Abbas A. Rizvi, 2018, Pharmacogenetics and genomics.

Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)

G. Hortobagyi, Song Liu, C. Isaacs, 2011, Breast Cancer Research and Treatment.

Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.

S. Cummings, S. Loader, P. Rowley, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Dieter Niederacher, Ute Hamann, Alfons Meindl, 2008, American journal of human genetics.

RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.

F. Couch, O. Olopade, T. Rebbeck, 2007, American journal of human genetics.

Characterization of BRCA1 and BRCA2 mutations in a large United States sample.

Leif E. Peterson, Giovanni Parmigiani, Christopher I Amos, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.

Anne-Michelle Noone, Minetta C. Liu, A. Noone, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

W. Chung, D. Steinemann, F. Couch, 2019, British Journal of Cancer.

BRCA1 in hormonal carcinogenesis: basic and clinical research.

C. Isaacs, E. Rosen, S. Fan, 2005, Endocrine-related cancer.

BRCA1 in hormonal carcinogenesis: basic and clinical research.

C. Isaacs, E. Rosen, S. Fan, 2005, Endocrine-related cancer.

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

E. Petricoin, L. Esserman, N. Hylton, 2022, npj Breast Cancer.

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

D. Berry, E. Petricoin, L. Esserman, 2021, NPJ breast cancer.

Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.

J. Garber, H. Valdimarsdottir, C. Isaacs, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy.

Mark P Purdue, Barnett S Kramer, John K Gohagan, 2012, The New England journal of medicine.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

Mads Thomassen, Nina Ditsch, Muhammad Usman Rashid, 2015, JAMA.

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Communications.

Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.

Katherine M. Tucker, W. Chung, R. Nussbaum, 2018, Journal of the National Cancer Institute.

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study

Stephanie A Cohen, F. Couch, O. Olopade, 2016, British Journal of Cancer.

Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study

Charis Eng, Fergus Couch, Kevin Sweet, 2013, British Journal of Cancer.

Management Updates for Women with a BRCA1 or BRCA2 Mutation

C. Isaacs, Rachel Nusbaum, 2012, Molecular Diagnosis & Therapy.

The Genetic Epidemiology of Hereditary Breast Cancer

T. Rebbeck, D. Easton, A. Antoniou, 2007 .

Risk Prediction in Breast Cancer

T. Rebbeck, R. Eeles, C. Isaacs, 2007 .

Utilization of BRCA 1 / BRCA 2 Mutation Testing in Newly Diagnosed Breast Cancer Patients

C. Isaacs, B. Peshkin, M. Schwartz, 2005 .

BRCA1/2 testing: complex themes in result interpretation.

C. Isaacs, B. Peshkin, C. Lerman, 2001, Journal of Clinical Oncology.

Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis

M. Pujana, C. Isaacs, V. Jin, 2017, Nature Communications.

Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155

C. Deng, M. Greene, C. Isaacs, 2011, Nature Medicine.

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

Jane E. Carpenter, A. Whittemore, W. Chung, 2016, Nature Communications.

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Rosalind Eeles, Susan L Neuhausen, Fergus J Couch, 2010, JAMA.

Pooled analysis of active cigarette smoking and invasive breast cancer risk in 14 cohort studies.

M. Thun, I. Gram, H. Adami, 2016, International journal of epidemiology.

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

A. Whittemore, W. Chung, L. Kiemeney, 2022, European Journal of Human Genetics.

PLAC1 as a serum biomarker for breast cancer

C. Isaacs, R. Glazer, Hongyan Yuan, 2018, PLoS ONE.

A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.

J. Hanfelt, C. Isaacs, D. Hayes, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patients.

C. Isaacs, V. Sheppard, S. O’Neill, 2015, Clinical breast cancer.

Narrowing racial gaps in breast cancer chemotherapy initiation: the role of the patient–provider relationship

Minetta C. Liu, C. Isaacs, J. Mandelblatt, 2013, Breast Cancer Research and Treatment.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.

E. Gehan, C. Isaacs, D. Hayes, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRCA1 deficiency in mature CD8+ T lymphocytes impairs antitumor immunity

C. Isaacs, Xiaowen Zhang, Huai-Chin Chiang, 2023, Journal for ImmunoTherapy of Cancer.

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy.

N. Hylton, L. Pusztai, D. Yee, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

New prognostic factors for breast cancer recurrence.

C. Isaacs, D. Hayes, V. Stearns, 2001, Seminars in oncology.

Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity?

A. Saykin, J. V. Van Meter, C. Isaacs, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA )

R. Nussbaum, V. Pankratz, F. Couch, 2011 .

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials

D. Alberts, P. Brown, A. Berchuck, 2017, Clinical Cancer Research.

BRCA1/2 test results impact risk management attitudes, intentions, and uptake

H. Valdimarsdottir, C. Isaacs, B. Peshkin, 2010, Breast Cancer Research and Treatment.

BRCA1/2 mutations and triple negative breast cancers.

C. Isaacs, B. Peshkin, Claudine Isaacs, 2010, Breast disease.

Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction.

Suzanne O'Neill, Suzanne Leaman, H. Valdimarsdottir, 2009, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

O. Olopade, T. Rebbeck, A. Levin, 1999, Journal of the National Cancer Institute.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Lara E Sucheston-Campbell, Simon G. Coetzee, Dennis J. Hazelett, 2017, Nature Genetics.

Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

W. Chung, V. Pankratz, F. Couch, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.

O. Olopade, T. Rebbeck, A. Levin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Utilization of BRCA1/BRCA2 Mutation Testing in Newly Diagnosed Breast Cancer Patients

C. Isaacs, B. Peshkin, M. Schwartz, 2005, Cancer Epidemiology Biomarkers & Prevention.

Results of a randomized controlled trial of a decision support intervention for disclosing maternal BRCA genetic test results to children and adolescents

J. Garber, C. Isaacs, B. Peshkin, 2023, PEC innovation.

Improving our model of cascade testing for hereditary cancer risk by leveraging patient peer support: a concept report

C. Isaacs, M. Robson, B. Peshkin, 2021, Hereditary cancer in clinical practice.

Information and support needs of young women regarding breast cancer risk and genetic testing: adapting effective interventions for a novel population

C. Isaacs, B. Peshkin, S. Friedman, 2018, Familial Cancer.

Understanding the Needs of Young Women Regarding Breast Cancer Risk Assessment and Genetic Testing: Convergence and Divergence among Patient-Counselor Perceptions and the Promise of Peer Support

C. Isaacs, B. Peshkin, C. Evans, 2016, Healthcare.

Providers’ Perceptions and Practices Regarding BRCA1/2 Genetic Counseling and Testing in African American Women

C. Isaacs, B. Peshkin, V. Sheppard, 2011, Journal of Genetic Counseling.

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

J. Gregg, C. Isaacs, S. Badve, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2

Lenora E. Johnson, M D Schwartz, C. Isaacs, 2001, Cancer.

The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

W. Chung, F. Couch, O. Olopade, 2021, Genetics in Medicine.

BRCA Mutation Testing in Determining Breast Cancer Therapy

C. Isaacs, K. Smith, Claudine Isaacs, 2011, Cancer journal.

Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes.

F. Couch, O. Olopade, T. Rebbeck, 2011, Cancer research.

Breast Cancer Risk Modifiers

T. Rebbeck, G. Chenevix-Trench, R. Milne, 2007 .

Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers

O. Olopade, B. Karlan, P. Møller, 2006, Breast Cancer Research.

A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

W. Chung, V. Pankratz, F. Couch, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Genetic Variation in IGF 2 and HTRA 1 and Breast Cancer Risk among BRCA 1 and BRCA 2 Carriers

F. Couch, O. Olopade, T. Rebbeck, 2011 .

Long‐term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance

C. Isaacs, Elizabeth Poggi, B. Peshkin, 2012, Cancer.

Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.

O. Olopade, T. Rebbeck, R. Eeles, 2006, The Lancet. Oncology.

Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis

C. Isaacs, D. Hayes, V. Stearns, 2001, Journal of mammary gland biology and neoplasia.

Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.

F. Couch, O. Olopade, T. Rebbeck, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

Jane E. Carpenter, A. Whittemore, S. Cross, 2016, Breast Cancer Research.

Syddansk Universitet Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12 p 11 locus

Jane E. Carpenter, Jaana M. Hartikainen, S. Cross, 2016 .

Uptake of BRCA1/2 Genetic Testing in a Randomized Trial of Telephone Counseling

J. Garber, H. Valdimarsdottir, C. Isaacs, 2014, Genetics in Medicine.

The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families

C. Isaacs, B. Peshkin, M. Schwartz, 2019, Journal of Cancer Education.

Randomized Noninferiority Trial of Telephone vs In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer: A 12-Month Follow-Up

J. Garber, H. Valdimarsdottir, C. Isaacs, 2017, JNCI cancer spectrum.

The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families

C. Isaacs, B. Peshkin, M. Schwartz, 2019, Journal of Cancer Education.

Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer

C. Isaacs, J. Collins, 2020, The Breast Journal.

Association of breast cancer risk in BRCA 1 and BRCA 2 mutation carriers with genetic variants showing differential allelic expression

R. Nussbaum, F. Couch, O. Olopade, 2016 .

Breast cancer risk variants at 6 q 25 display different phenotype associations and regulate ESR 1 , RMND 1 and CCDC 170

Wei Zheng, Mads Thomassen, Nicholas A. Sinnott-Armstrong, 2016 .

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

W. Chung, R. Nussbaum, D. Steinemann, 2015, Breast Cancer Research.

Title Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA 1 and BRCA 2 mutation carriers

R. Nussbaum, D. Steinemann, V. Pankratz, 2015 .

phylogenetic approach identified mitochondrial haplogroup T 1 a 1 as inversely associated with breast cancer risk in BRCA 2 mutation carriers

W. Chung, D. Steinemann, V. Pankratz, 2015 .

Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.

F. Couch, T. Rebbeck, J. Benítez, 2011, Human molecular genetics.

Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample.

C. Isaacs, B. Peshkin, M. Schwartz, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.

M. Thun, F. Clavel-Chapelon, E. Riboli, 2010, Human molecular genetics.

Risk and Prevention for Highly Penetrant Genes

C. Isaacs, K. Khoury, Ami Chitalia, 2018, Current Breast Cancer Reports.

Predictors of genetic testing uptake in newly diagnosed breast cancer patients

H. Valdimarsdottir, C. Isaacs, B. Peshkin, 2020, Journal of surgical oncology.

Telephone versus in-person genetic counseling for hereditary cancer risk: Patient predictors of differential outcomes

J. Garber, H. Valdimarsdottir, C. Isaacs, 2021, Journal of telemedicine and telecare.

Patient Perceptions of Telephone vs. In-Person BRCA1/BRCA2 Genetic Counseling

J. Garber, H. Valdimarsdottir, C. Isaacs, 2016, Journal of Genetic Counseling.

A Multicenter Randomized Clinical Trial Evaluating Interleukin-2 Activated Hematopoietic Stem Cell Transplantation and Post-transplant IL-2 for High Risk Breast Cancer Patients

E. Gehan, C. Isaacs, D. Hayes, 2005, Breast Cancer Research and Treatment.

Erratum: Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155

C. Deng, M. Greene, C. Isaacs, 2011, Nature Medicine.

A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11.

Jane E. Carpenter, Daniel J. Park, Gary K. Chen, 2012, Human molecular genetics.

A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013).

E. Winer, G. Babiera, C. Hudis, 2016 .

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint

L. Esserman, W. Fraser Symmans, D. Yee, 2018, npj Breast Cancer.

Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results.

W. Willett, M. Pike, P. A. van den Brandt, 2014, Journal of the National Cancer Institute.

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

G. Hortobagyi, C. Isaacs, R. Livingston, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

D. Berry, E. Petricoin, L. Esserman, 2021, Nature Communications.

Novel molecular prognostic markers in breast cancer.

C. Isaacs, T. Goswami, Minal Shah, 2009, Expert Opinion in Medical Diagnostics.

Physical and psychological health in rare cancer survivors

C. Isaacs, D. Finkelstein, S. Domchek, 2017, Journal of Cancer Survivorship.

Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status

Peter Kraft, Sara Lindström, I-Min Lee, 2012, Journal of Medical Genetics.

Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.

D. Berry, L. Esserman, N. Hylton, 2020, JAMA oncology.

Risk Management for BRCA1/BRCA2 Mutation Carriers Without and With Breast Cancer

C. Isaacs, C. Mainor, 2020, Current Breast Cancer Reports.

Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS

C. Isaacs, B. Peshkin, M. Schwartz, 2012, Journal of Cancer Epidemiology.

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

W. Chung, M. Beckmann, P. Fasching, 2019, npj Breast Cancer.

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.

K. Gelmon, A. Tolcher, C. Isaacs, 1999, Journal of Clinical Oncology.

Population‐based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years

C. Isaacs, M. Schwartz, H. Tsai, 2015, Cancer.

SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.

C. Isaacs, M. Tan, S. Swain, 2017, The Oncologist.

Palbociclib in Metastatic Breast Cancer

C. Isaacs, F. Lynce, 2015 .

A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor.

C. Isaacs, P. Pohlmann, F. Lynce, 2023, Contemporary clinical trials communications.

J. VanMeter, A. Saykin, B. McDonald, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network

Adrian V. Lee, E. Mardis, C. Perou, 2020 .

Abstract GS5-02: Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158

J. Gregg, C. Isaacs, S. Badve, 2020 .

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.

D. Berry, L. Esserman, N. Hylton, 2021, JAMA oncology.

Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221)

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, G. Hortobagyi, 2018, Breast Cancer Research.

Factors associated with oxidative stress and cancer risk in the Breast and Prostate Cancer Cohort Consortium

S. Chanock, R. Hoover, D. Hunter, 2014, Free radical research.

Phase I I E valuation o f T halidomide i n P atients W ith Metastatic B reast C ancer

E. Winer, J. Hanfelt, C. Isaacs, 2000 .

Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers.

Daniel Krewski, Susan L Neuhausen, Jan Lubinski, 2010, Breast.

q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers

V. Pankratz, F. Couch, B. Bonanni, 2012 .

Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk

S. Edge, J. Freudenheim, C. Isaacs, 2011, BMC Cancer.

Prediction of benefit from adjuvant treatment in patients with breast cancer.

C. Isaacs, J. Eng-Wong, J. Eng‐Wong, 2010, Clinical Breast Cancer.

BRCA1 and BRCA2 in Underserved and Special Populations

T. Rebbeck, C. Isaacs, Bifeng Zhang, 2007 .

Hereditary Breast Cancer

T. Rebbeck, C. Isaacs, 2007 .

Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis

C. Isaacs, P. Pohlmann, R. Schlegel, 2021, Biomedicines.

The Cancer Genetics Network: Recruitment Results and Pilot Studies

Prakash Nadkarni, Argyrios Ziogas, Hoda Anton-Culver, 2003, Public Health Genomics.

Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status

A. Berchuck, M. Greene, S. Buys, 2011, Cancer Prevention Research.

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers

T. Rebbeck, B. Weber, J. Garber, 2004 .

Modification of BRCA 1-Associated Breast and Ovarian Cancer Risk by BRCA 1-Interacting Genes

F. Couch, O. Olopade, T. Rebbeck, 2011 .

SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.

C. Isaacs, M. Tan, S. Swain, 2018 .

Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance)

H. Cohen, E. Winer, C. Hudis, 2017, Breast Cancer Research and Treatment.

An 8-week exercise study to improve cancer treatment related fatigue and QOL among African American breast cancer patients undergoing radiation treatment: A pilot randomized clinical trial.

C. Isaacs, C. Dash, K. Makambi, 2023, Journal of the National Medical Association.

An exercise trial to reduce cancer related fatigue in African American breast cancer patients undergoing radiation therapy: Design, rationale, and methods.

C. Isaacs, C. Dash, K. Makambi, 2016, Contemporary Clinical Trials.

Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65

C. Isaacs, V. Sheppard, M. Schwartz, 2017, Breast Cancer Research.

Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.

C. Isaacs, M. Schwartz, H. Tsai, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901

H. Cohen, E. Winer, C. Hudis, 2014, Journal of Cancer Survivorship.

Trends in the Use of Cardiac Imaging for Women with Newly Diagnosed Breast Cancer

C. Isaacs, A. Barac, A. Potosky, 2020, Journal of Cardiovascular Translational Research.

Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.

C. Isaacs, B. Peshkin, M. Schwartz, 2018, Translational behavioral medicine.

Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65

C. Isaacs, V. Sheppard, M. Schwartz, 2017, Breast Cancer Research.

Pretreatment Psychoneurological Symptoms and Their Association With Longitudinal Cognitive Function and Quality of Life in Older Breast Cancer Survivors.

A. Saykin, B. McDonald, C. Isaacs, 2019, Journal of pain and symptom management.

Pre-treatment psychoneurological symptoms and their association with longitudinal cognitive function and quality of life in older breast cancer survivors

A. Saykin, B. McDonald, C. Isaacs, 2018 .

Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.

H. Cohen, E. Winer, C. Hudis, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.

H. Cohen, E. Winer, S. Edge, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spiritual faith and genetic testing decisions among high-risk breast cancer probands.

C. Isaacs, B. Peshkin, M. Schwartz, 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV).

C. Isaacs, E. Stepanski, R. Hermann, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of women at increased risk for hereditary breast cancer.

C. Isaacs, K. Smith, Claudine Isaacs, 2007, Breast disease.

A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: Final results

M. Ellis, Y. Tao, L. Harris, 2005 .

Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data.

A. Neugut, C. Isaacs, J. Mandelblatt, 2015, Journal of oncology practice.

Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotype

A. Saykin, B. McDonald, C. Isaacs, 2019, Cancer.

Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.

Nandita Mitra, Georgia Chenevix-Trench, Susan L Neuhausen, 2009, Cancer research.

Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901.

H. Cohen, W. Barry, C. Isaacs, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.

M. Pike, T. Rebbeck, R. Eeles, 2016, JAMA oncology.

A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.

Baljit Singh, C. Isaacs, D. Hayes, 2003, Clinical Cancer Research.

Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores.

C. Isaacs, J. Mandelblatt, C. Schechter, 2019, Journal of the National Cancer Institute.

A Peer-Led Decision Support Intervention Improves Decision Outcomes in Black Women with Breast Cancer

C. Isaacs, V. Sheppard, S. Willey, 2013, Journal of Cancer Education.

Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL

L. Esserman, M. Troxell, D. Yee, 2018 .

Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer

C. Isaacs, S. Swain, A. Tan, 2020, Frontiers in Oncology.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

Anne Wallace, Emanuel F Petricoin, Rita Nanda, 2015, Clinical Cancer Research.

Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety

C. Isaacs, D. Venzon, E. Makariou, 2016, Cancer Prevention Research.

Development and Validation of a Simulation Model–Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions

C. Isaacs, J. Sparano, A. Kurian, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers

C. Isaacs, Elizabeth Poggi, B. Peshkin, 2014, Hereditary cancer in clinical practice.

Poly(ADP-Ribose) Inhibition: Exploring a New Approach to Breast Cancer Prevention in BRCA1/2 Mutation Carriers

C. Isaacs, K. Smith, 2011 .

Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)

H. Cohen, C. Isaacs, J. Clapp, 2017, Breast Cancer Research and Treatment.

Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers

C. Isaacs, Elizabeth Poggi, B. Peshkin, 2014, Hereditary Cancer in Clinical Practice.

A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901.

H. Cohen, E. Winer, C. Hudis, 2013, Journal of geriatric oncology.

Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence score as an exemplar.

R. Street, C. Isaacs, S. Vadaparampil, 2020, Patient education and counseling.

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

C. Isaacs, M. Tan, S. Swain, 2019, Breast Cancer Research and Treatment.

Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221)

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, G. Hortobagyi, 2018, Breast Cancer Research.

Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study

C. Isaacs, J. Warren, A. Fu, 2014, Breast Cancer Research and Treatment.

Long‐term trajectories of self‐reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)

H. Cohen, B. Pitcher, C. Isaacs, 2016, Cancer.

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.

Rosalyn W. Sayaman, L. Esserman, N. Hylton, 2023, Cancer cell.

Abstract PD2-12: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive (HR+) metastatic breast cancer (MBC) with prior chemotherapy for advanced disease (TBCRC 035) A phase II study with pharmacodynamics markers

H. Rugo, C. Isaacs, A. Wolff, 2019, Poster Discussion Abstracts.

Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines

C. Isaacs, B. Peshkin, S. Swain, 2016, Breast Cancer Research and Treatment.

Venous thromboembolic disease and stroke in women taking tamoxifen for breast cancer chemoprevention.

C. Isaacs, 2005, Clinical advances in hematology & oncology : H&O.

Evaluation of a virtual dialogue method for breast cancer patient education.

William G Harless, W. Harless, C. Isaacs, 2009, Patient Education and Counseling.

Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial

L. Esserman, O. Olopade, L. Pusztai, 2022, Cancer Research.

Abstract LB-216: NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancer

B. Ramaswamy, C. Shapiro, C. Isaacs, 2016 .

Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function

C. Isaacs, M. Tan, S. Swain, 2021, Breast Cancer Research and Treatment.

Effect of screening on ovarian cancer mortality in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer randomized screening trial.

P. Prorok, J. Rathmell, P. Hartge, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics

C. Isaacs, J. Mandelblatt, C. Schechter, 2021, Cancer medicine.

The Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer

C. Isaacs, Erin E. Roesch, 2015 .

Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.

C. Isaacs, T. Biagi, R. Amdur, 2020, Clinical Breast Cancer.

Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer

G. Hortobagyi, C. Isaacs, W. Barlow, 2023, JAMA network open.

Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

D. Berry, N. Hylton, D. Yee, 2017 .

Abstract P6-11-04: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

D. Berry, N. Hylton, D. Yee, 2017 .

A Peer-Led Decision Support Intervention Improves Decision Outcomes in Black Women with Breast Cancer

C. Isaacs, V. Sheppard, S. Willey, 2013, Journal of Cancer Education.

The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers

F. Couch, D. Easton, K. Offit, 2012, Breast Cancer Research and Treatment.

Effects of coping style and BRCA1 and BRCA2 test results on anxiety among women participating in genetic counseling and testing for breast and ovarian cancer risk.

C. Isaacs, B. Peshkin, M. Schwartz, 2001, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

D. Berry, L. Esserman, N. Hylton, 2020 .

Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL

D. Berry, L. Esserman, N. Hylton, 2020 .

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint

L. Esserman, W. Fraser Symmans, C. Ewing, 2018, npj Breast Cancer.

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer

Minetta C. Liu, C. Isaacs, M. Goetz, 2023, JAMA oncology.

How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing.

C. Isaacs, F. Lynce, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.

C. Isaacs, S. Swain, A. Tan, 2019, Journal of Clinical Oncology.

Tumor mutational load in gynecological and breast cancer.

C. Isaacs, A. Tan, Z. Gatalica, 2017 .

Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study

H. Cohen, A. Saykin, B. McDonald, 2019, Cancer.

Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.

M. Gnant, C. Isaacs, A. DeMichele, 2022, Journal of Clinical Oncology.

Measuring high‐risk parents' opinions about direct‐to‐consumer genetic testing for adult‐onset inherited cancer syndromes in their adolescent and young adult children

B. Wilfond, C. Isaacs, B. Peshkin, 2023, Journal of genetic counseling.

Practical aspects of delivering hereditary cancer risk counseling.

C. Isaacs, B. Peshkin, M. Schwartz, 2007, Seminars in oncology.

Plasma levels of interleukin‐6 mediate neurocognitive performance in older breast cancer survivors: The Thinking and Living With Cancer study

A. Saykin, B. McDonald, C. Isaacs, 2023, Cancer.

Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

D. Berry, L. Esserman, N. Hylton, 2016 .

Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

D. Berry, L. Esserman, N. Hylton, 2016 .

Rapid progression of prostate cancer in men with a BRCA2 mutation

P Ghadirian, F. Couch, D. Horsman, 2008, British Journal of Cancer.

Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint

I. L. Fernandes, L. Esserman, D. Yee, 2019, npj Breast Cancer.

Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL

L. Esserman, N. Hylton, D. Yee, 2019, Clinical Trials.

Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

D. Lynch, J. Gohagan, P. Prorok, 2010, Journal of the National Cancer Institute.

Screening in the randomized Prostate , lung , colorectal , and Ovarian ( PlcO ) cancer Screening trial

D. Lynch, J. Gohagan, P. Prorok, 2010 .

Clinically relevant changes in family history of cancer over time.

L. Strong, A. Ziogas, H. Anton-Culver, 2011, Journal of the American Medical Association (JAMA).

Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

D. Berry, L. Esserman, N. Hylton, 2021 .

BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.

K Offit, A Oliphant, S. Loader, 1997, JAMA.

Breast Cancer Research and Treatment 2001 Reviewers

D. Berry, L. Holmberg, D. Alberts, 2004, Breast Cancer Research and Treatment.

Hereditary Breast Cancer

T. Rebbeck, C. Isaacs, Claudine Isaacs, 2007, Cancer Plus.

Initiation of Trastuzumab by Women Younger Than 64 Years for Adjuvant Treatment of Stage I-III Breast Cancer.

C. Isaacs, M. Schwartz, H. Tsai, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

Jane E. Carpenter, A. Whittemore, S. Cross, 2016, Breast Cancer Research.

Analysis of Co-Aggregation of Cancer Based on Registry Data

D. Bowen, L. Strong, H. Anton-Culver, 2006, Public Health Genomics.

Abstract P2-18-09: TBCRC 013: A prospective analysis of the role of surgery in stage IV breast cancer

E. Winer, G. Babiera, L. Norton, 2013 .

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Jane E. Carpenter, W. Chung, M. Beckmann, 2019, npj Breast Cancer.

Abstract CN04-04: Phase II trial of bexarotene in women at high risk of breast cancer: Comparison of protein and RNA biomarkers

S. Hilsenbeck, P. Brown, N. Sneige, 2008 .

Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.

V. Pankratz, F. Couch, O. Olopade, 2010, Cancer research.

Common variants at 12 p 11 , 12 q 24 , 9 p 21 , 9 q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers

V. Pankratz, F. Couch, David Evans, 2017 .

Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers

F. Couch, O. Olopade, T. Rebbeck, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Null Results in Brief Common Genetic Variation at BARD 1 Is Not Associated with Breast Cancer Risk in BRCA 1 or BRCA 2 Mutation Carriers

O. Olopade, T. Rebbeck, R. Eeles, 2011 .

Abstract P1-18-13: Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC) participating in the PALOMA trials

H. Rugo, C. Isaacs, Xin Huang, 2022, Cancer Research.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

L. Esserman, N. Hylton, O. Olopade, 2016, The New England journal of medicine.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.

C. Isaacs, M. Tan, S. Swain, 2017, The oncologist.

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials

D. Alberts, P. Brown, A. Berchuck, 2017, Clinical Cancer Research.

A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk.

L. Kiemeney, P. Fasching, R. Nussbaum, 2018, Cancer research.

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

F. Couch, O. Olopade, J. Klijn, 2002, Journal of the National Cancer Institute.

Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.

F. Couch, O. Olopade, T. Rebbeck, 2009, Cancer research.

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

C. Isaacs, Bing-he Xu, F. André, 2014, The Lancet. Oncology.

Treatment of primary breast tumors in de novo metastatic breast cancer.

C. Isaacs, Theresa M. Lee, 2014, Clinical advances in hematology & oncology : H&O.

Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

K. Gelmon, M. Gnant, C. Isaacs, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.

J. Gohagan, P. Prorok, J. Rathmell, 2011, JAMA.

Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

D. Lynch, J. Gohagan, P. Prorok, 2010, Journal of the National Cancer Institute.

Hot flushes

C. Isaacs, D. Hayes, J. F. Lopez, 2002, The Lancet.

Genetic Testing and Counseling Issues

T. Rebbeck, C. Isaacs, J. Stopfer, 2007 .

Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901.

H. Cohen, W. Barry, C. Isaacs, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Psychosocial Outcomes of BRCA1/BRCA2 Testing: Differences across Affected Status and Risk-Reducing Surgery Choice

C. Isaacs, Elizabeth Poggi, B. Peshkin, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

Jack A. Taylor, S. Cross, C. Vachon, 2020, Genetic epidemiology.

Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?

F. Couch, T. Rebbeck, R. Eeles, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation and management of women with BRCA1/2 mutations.

C. Isaacs, B. Peshkin, 2005, Oncology.

Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).

A. Glas, L. Esserman, L. Pusztai, 2023, Journal of Clinical Oncology.